Synthetic cannabinoids, a large, chemically heterogeneous group of psychoactive substances known as “legal highs”, includes various aromatic herbs treated with a mixture of artificially synthesized cannabinoids. The popularity of synthetic cannabinoids, despite the restrictive legislative measures and the medical consequences associated with the use, is growing annually among consumers.
Synthetic cannabinoids are designed to replicate the psychoactive effects of D9-tetrahydrocannabinol (D9-THC or THC) synthesized from plant hemp. Shadow manufacturers of synthetic cannabinoids constantly bypass the legislative restrictions adopted in many countries of the world, synthesizing new substances with a modified chemical formula, and accompanying products with the words “not for ingestion,” “not swallow,” “not for human use” —that brings many legal problems.
In the past 3-4 years, the number of hospitalizations for urgent indications associated with the use of synthetic cannabinoids has increased, and the number of deaths directly related to the use of synthetic cannabinoids also increases. This situation emphasizes the need to reorganize the emergency system for this group of patients and shows the unpreparedness of the professional community to enter the shadow market